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Abstract 
Virilization is the medical term for describing a female who develops characteristics asso-
ciated with male hormones (androgens) at any age, or when a newborn girl shows signs 
of prenatal male hormone exposure at birth. In girls, androgen levels are low during 
pregnancy and childhood. A first physiologic rise of adrenal androgens is observed at 
the age of 6 to 8 years and reflects functional activation of the zona reticularis of the ad-
renal cortex at adrenarche, manifesting clinically with first pubic and axillary hairs. Early 
adrenarche is known as “premature adrenarche.” It is mostly idiopathic and of uncer-
tain pathologic relevance but requires the exclusion of other causes of androgen excess 
(eg, nonclassic congenital adrenal hyperplasia) that might exacerbate clinically into vir-
ilization. The second modest physiologic increase of circulating androgens occurs then 
during pubertal development, which reflects the activation of ovarian steroidogenesis 
contributing to the peripheral androgen pool. However, at puberty initiation (and be-
yond), ovarian steroidogenesis is normally devoted to estrogen production for the de-
velopment of secondary female bodily characteristics (eg, breast development). Serum 
total testosterone in a young adult woman is therefore about 10- to 20-fold lower than in 
a young man, whereas midcycle estradiol is about 10- to 20-fold higher. But if androgen 
production starts too early, progresses rapidly, and in marked excess (usually more than 
3 to 5 times above normal), females will manifest with signs of virilization such as mas-
culine habitus, deepening of the voice, severe acne, excessive facial and (male typical) 
body hair, clitoromegaly, and increased muscle development. Several medical condi-
tions may cause virilization in girls and women, including androgen-producing tumors 
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of the ovaries or adrenal cortex, (non)classical congenital adrenal hyperplasia and, more 
rarely, other disorders (also referred to as differences) of sex development (DSD). The 
purpose of this article is to describe the clinical approach to the girl with virilization at 
puberty, focusing on diagnostic challenges. The review is written from the perspective of 
the case of an 11.5-year-old girl who was referred to our clinic for progressive, rapid onset 
clitoromegaly, and was then diagnosed with a complex genetic form of DSD that led to 
abnormal testosterone production from a dysgenetic gonad at onset of puberty. Her gen-
etic workup revealed a unique translocation of an abnormal duplicated Y-chromosome 
to a deleted chromosome 9, including the Doublesex and Mab-3 Related Transcription 
factor 1 (DMRT1) gene.
Learning Objectives 
Identify the precise pathophysiologic mechanisms leading to virilization in girls at pu-
berty considering that virilization at puberty may be the first manifestation of an endo-
crine active tumor or a disorder/difference of sex development (DSD) that remained 
undiagnosed before and may be life-threatening. Of the DSDs, nonclassical congenital 
adrenal hyperplasia occurs most often.
Provide a step-by-step diagnostic workup plan including repeated and expanded 
biochemical and genetic tests to solve complex cases.
Manage clinical care of a girl virilizing at puberty using an interdisciplinary team approach.
Care for complex cases of DSD manifesting at puberty, such as the presented girl with 
a Turner syndrome-like phenotype and virilization resulting from a complex genetic 
variation.
Key Words: virilization, androgen excess, disorders/differences of sex development (DSD), endocrine active tumors, 
genetic disorders of androgen excess
An 11.5-year-old girl was referred to our center for pro-
gressive clitoromegaly for 6 months. Her medical history 
revealed prematurity of 36 weeks’ gestation with a birth 
weight of 2920 g (–0.70 standard deviation score [SDS]) 
and length of 45.5  cm (–1.85 SDS). At birth, typical fe-
male external genitalia were noted without any signs of 
virilization (eg, no clitoromegaly). The child was assigned 
and raised as female. She was followed by a general pedi-
atrician who noted a mild delay in psychomotor develop-
ment for unknown reasons, which did not prompt further 
neurodevelopmental and genetic workup. The girl had 
pubarche and thelarche at around age 10 years. At pres-
entation aged 11.5 years, physical examination revealed a 
height of 139.4 cm (–1.12 SDS), a weight of 43.6 lb (0.47 
SDS), and body mass index of 22.4  kg/m2 (1.59 SDS), 
indicating overweight. Blood pressure was normal. She 
presented no syndromic features (eg, no typical signs for 
Turner syndrome [TS] or hypercortisolism). She showed a 
normal cardiopulmonary and abdominal examination; no 
intra-abdominal or inguinal masses were palpable. External 
genitalia inspection revealed a marked clitoromegaly of 
3.5 × 1.5 cm in size but was otherwise typical female. No 
other signs of virilization such as voice deepening or severe 
acne were noted. Pubertal stage according to Tanner was 
pubic hair V, breast II, axillary hair II. In addition, rich 
bodily hair was noted consistent with hypertrichosis, but a 
Ferriman and Gallwey score was not assessed.
Background
Virilization at puberty is a rare disease manifestation of se-
vere androgen excess, most often occurring in girls who 
have an undiagnosed underlying genetic condition or an ac-
quired disorder affecting the adrenal glands or gonads. By 
contrast, mild to moderate hyperandrogenism may mani-
fest with hirsutism at puberty and is characterized by exces-
sive hair growth in androgen-sensitive areas, but without 
additional signs of masculinization. Hirsutism may be idio-
pathic or the first sign of a polycystic ovary syndrome (1).
In 46,XX adolescents, virilization can result from se-
vere hyperandrogenism because of underlying excessive 
production or abnormal metabolism of adrenal or gonadal 
androgens. Paradoxically, in 46,XY females, virilization 
around puberty points toward a possible condition of se-
vere undervirilization during sex determination and differ-
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phenotype that may go unrecognized until puberty. At that 
time, high circulating androgens may then lead to the de-
velopment of masculine bodily characteristics including 
deepening of the voice, clitoromegaly, severe acne, and se-
vere, early-onset hirsutism.
Very rarely, drug abuse and environmental toxins 
may play a role and should be considered in unsolved 
cases (2). Timely investigation of the girl with viriliza-
tion at puberty is essential, particularly if associated 
with a sudden onset of symptoms and/or a rapid pro-
gression because this should raise immediate concern of 
an androgen-secreting tumor of the ovaries or adrenal 
cortex (3-6).
Adrenal and Gonadal Tumors
Adrenocortical tumors are very rare (<0.2% of pediatric 
malignancies) and produce mostly not only excess an-
drogens but also glucocorticoids (80%), thus manifesting 
with signs of hypercortisolism (Cushing syndrome) (6). 
Furthermore, they are often associated with particular 
genetic syndromes such as the Beckwith-Wiedemann syn-
drome or with a familial genetic predisposition to cancers 
(mostly from p53 mutations) (6).
Likewise, (androgen-secreting) tumors of the ovary are 
rare (4). The most common pediatric ovarian neoplasms are 
teratomas. These are germ cell tumors (GCTs) that originate 
from pluripotent germ cells. The majority are benign and hor-
monally inactive. Dysgerminoma is the most common malig-
nant GCTs, developing from a preexisting gonadoblastoma, 
predominantly in persons with gonadal dysgenesis. In fact, 
a GCT may be the first manifestation of an undiagnosed 
disorder of sex development (DSD) and should raise suspi-
cion and specific workup (7). Sertoli-Leydig cell tumors are 
exceedingly rare malignancies that produce androgens and 
cause severe virilization. They have a high association with 
the DICER1 syndrome, a genetic disorder with increased 
risk for developing tumors in the lungs, kidneys, ovaries, thy-
roid, and several other locations (8).
Congenital Adrenal Hyperplasia
The most common genetic cause of virilization before 
and at puberty is congenital adrenal hyperplasia (CAH) 
(Table  1). In addition, rarer forms of DSD affecting go-
nadal development and/or sex steroid synthesis and action 
need to be considered. CAH is in most cases caused by 
21-hydroxylase deficiency resulting from autosomal reces-
sive variants of the CYP21A2 gene, which has a prevalence 
of its classic form of 1 in 15,000 births worldwide (3, 9). 
Numerous genetic variants lead to glucocorticosteroid de-
ficiency and adrenal androgen excess (3, 9). Virilization of 
the external genitalia at birth is therefore frequently seen in 
girls with more severe forms of classic CYP21A2 deficiency, 
and diagnosis is usually made by clinical manifestation and 
neonatal screening in most countries (3, 9). By contrast, 
prevalence of the less severe, nonclassic/late-onset form of 
CAH is estimated more than 10-fold higher in the general 
population, and it is diagnosed later in childhood, in ado-
lescence, or even only in adulthood (9). Nonclassic CAH 
typically manifests with hyperandrogenism resulting in 
premature pubarche, accelerated linear growth, advanced 
skeletal maturation, and signs of virilization including 
clitoromegaly (10).
Much rarer forms of CAH manifesting as late-onset 
virilization in individuals with a 46,XX karyotype include 
deficiencies of 3β-hydroxysteroid dehydrogenase type 2 
and 11β-hydroxylase caused by variants in the HSD3B2 
and CYP11B1 genes, respectively (3, 11, 12). Even vari-
ants in the cytochrome P450 oxidoreductase (POR) gene, 
a cofactor supporting several enzymes of steroidogenesis 
(including CYP21A1, CYP17A1, and CYP19A1) could 
explain virilization of affected females at puberty, 
Table 1. Genetic disorders of sex development associated with pubertal virilization
Gonadal dysgenesis
 -Structural or numerical aberrations of sex chromosomes
 -Variants in genes involved in gonadal development (eg, WT1, NR5A1, DMRT1)
46,XX congenital adrenal hyperplasia (CAH)
 -21-hydroxylase deficiency (CYP21A2)
 -11-hydroxylase deficiency (CYP11B1)
 -3β-hydroxysteroid dehydrogenase deficiency (HSD3B2)
 -Cytochrome P450 oxidoreductase deficiency (POR)
46,XX aromatase deficiency (CYP19A1)
46,XY defects of androgen synthesis and action
 -17β hydroxysteroid dehydrogenase deficiency (HSD17B3)
 -5α reductase deficiency (SRD5A2)
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although so far only a polycystic ovary syndrome–like 
phenotype has been described in young women, whereas 
both 46,XY undervirilization and 46,XX virilization re-
sulting from genetic variants of POR are typical at birth 
(3, 13). In addition, girls harboring autosomal recessive 
CYP19A1 variants may also present at puberty with vir-
ilization because aromatase deficiency leads to elevated 
androgens and low estrogens (14). However, more typic-
ally these girls experience virilization in utero, have am-
biguous genitalia at birth, and may suffer from ovarian 
cysts during childhood.
Disorders of Androgen Synthesis and Action, 
Testicular Dysgenesis, and Ovotesticular DSD
Sudden virilization at puberty can be seen in 46,XY girls 
who have a disorder of androgen synthesis or action 
(Table 1). To the former group belong genetic variants of 
the SRD5A2 gene, catalyzing for DHT production from 
testosterone (15) and the HSD17B3 gene, converting 
androstenedione into testosterone (16). Why testicular tes-
tosterone or DHT production is more efficient than pre-
natally in pubertal girls who have these conditions has been 
attributed in part to isoenzyme activation at puberty (3), 
but remains overall insufficiently understood. Massive vir-
ilization and clarification of the underlying diagnosis may 
lead to sex/gender reassignment in these individuals in ado-
lescence in up to 50% of cases (17).
Partial androgen insensitivity syndrome is a form of 
testicular DSD caused by pathogenic mutations in the 
Androgen Receptor gene, resulting in a decreased sensi-
tivity to the actions of androgens and has a prevalence of 1 
to 5:100,000 (18, 19). The 46,XY females with partial an-
drogen insensitivity syndrome and typical female-looking 
external genitalia at birth may present signs of external 
genital masculinization, including clitoromegaly or pos-
terior labial fusion later in childhood or puberty. (17).
Various forms of gonadal dysgenesis (ie, incomplete tes-
ticular or ovarian differentiation) can also lead to viriliza-
tion of girls with puberty after initial manifestation with a 
typical female phenotype at birth (Table 1). Chromosomal 
aberrations and pathogenic variants in several genes in-
volved in the determination of the (bipotential) gonads and 
their differentiation may be the underlying cause (20). Some 
of these genetic anomalies will cause isolated DSD, whereas 
others are associated with additional developmental de-
fects in other organ systems and may form a characteristic 
syndrome. For example, heterozygous dominant-negative 
mutations of the Wilms tumor suppressor gene (WT1) on 
chromosome 11 can lead to the Denys-Drash syndrome, 
which is associated with kidney and gonad malformations 
and a high risk for developing a Wilms tumor (21). The 
46,XY babies with Denys-Drash syndrome have varying 
degrees of gonadal dysgenesis, leading to ambiguous ex-
ternal genitalia or even a female phenotype with variable 
virilization during later pubertal development depending 
on presence of functional testicular tissue (21). Moreover, 
spontaneous virilization at puberty has been reported in 
several cases with nonsyndromic 46,XY DSD resulting 
from NR5A1/SF1 variants (22, 23). In these cases, testis 
histology revealed dysplastic gonads with Leydig cell hyper-
plasia at puberty. Interestingly, development of an ovotestis 
(ovotesticular DSD) has also been reported in a 46,XY sub-
ject with a deletion of NR5A1 and in some 46,XX subjects 
harboring the NR5A1 variants p.Arg92Trp/Gln (22).
Clinical Evaluation
A thorough history and a focused clinical examination are 
crucial for successful diagnostic evaluation of patients with 
signs of severe androgen excess (24). Fig. 1 summarizes in-
vestigations that are recommended in the workup of a girl 
with virilization at puberty. Main differential diagnoses are 
included in the overview.
Medical History
The medical history should include pregnancy and family 
history (eg, tumors, fertility issues), birth weight and ges-
tational age at birth, somatic development and growth, 
age of adrenarche and thelarche, as well as menarche 
and menstrual characteristics (if already applicable). The 
timing and progression of the signs of virilization, such as 
clitoromegaly, acne, and hirsutism, along with a record of 
previous therapies (eg, hair removal procedures), are im-
portant for the diagnostic evaluation and management. 
History should include questions regarding virilization of 
the external genitalia (eg, clitoromegaly) or deepening of 
voice and breast atrophy.
Physical Examination
In the physical examination, blood pressure, height, weight 
and body mass index, waist-to-hip ratio, and signs of viril-
ization, such as severe acne, hirsutism, and alopecia, should 
be assessed. The Ferriman and Gallwey score may be used 
to score hirsutism (25). It is also recommended to search 
for signs of Cushing syndrome such as rounded face, pink 
or purple stretch marks on the skin, muscle wasting, and 
centripetal fat distribution. Furthermore, it is important 
to determine the pubertal stage and perform a thorough 
examination of the external genital region looking for the 
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Laboratory Investigations and Imaging Studies
Laboratory evaluations are essential in the workup of vir-
ilization (24). First-line investigations should include at 
least serum testosterone, dehydroepiandrosterone-sulfate 
(DHEA-S) and 17-hydroxyprogesterone (17OHP). Serum 
total testosterone levels are often more than 3 times ele-
vated in patients with androgen-secreting ovarian tumors 
(26). DHEA-S (and adrenal androgen precursors such as 
DHEA and androstenedione together with glucocortic-
oids) are markedly elevated with adrenal tumors (27). 
Markedly increased 17OHP serum levels (3, 9) (or maybe 
21-deoxycortisol in the future (28)), suggest CAH re-
sulting from 21-hydroxylase deficiency. This diagnosis 
may be confirmed by a simple ACTH test and/or a tar-
geted genetic test, if biochemical results are equivocal or 
genetical counseling is desired (9). Guided by the clinical 
findings and first laboratory results, imaging studies should 
ensue, including abdominal ultrasound, computed tomog-
raphy and/or magnetic resonance imaging of the adrenal 
glands and the pelvic organs to exclude androgen-secreting 
ovarian or adrenal tumors.
Second-line investigations (29) may include an ACTH 
stimulation test for evaluating adrenal gland function in 
cases of mildly elevated or normal basal 17OHP to ex-
clude milder forms of (nonclassic) CAH (9), or a more 
comprehensive plasma or urine steroid profile assessed by 
a chromatographic mass spectrometric method to find spe-
cific patterns of rarer forms of CAH (Table  1) (30, 31). 
Patients suspected for Cushing syndrome should be evalu-
ated with a 24-hour urine free cortisol, a diurnal ACTH 
and cortisol profile, and/or a low-dose dexamethasone sup-
pression test (3). Baseline gonadotrophins (FSH, LH) and 
estradiol should be measured and interpreted according to 
age-specific reference intervals. Suppressed or unmeasur-
ably low serum LH and FSH may be found before puberty 
onset or with severe androgen excess leading to a negative 
feedback blockade of the hypothalamic-pituitary-gonadal 
axis. Elevated LH and FSH is consistent with primary go-
nadal failure. Furthermore, measurement of serum Anti-
Müllerian hormone (AMH) help in classifying the different 
forms of DSDs with and without gonadal dysgenesis (32). 
Normally, AMH is produced in high amounts in immature 
Sertoli cells, but physiologically declines once pubertal tes-
tosterone production starts. In 46,XY DSD, AMH is low in 
gonadal dysgenesis, but normal or elevated with defects of 
androgen synthesis or action. In chromosomal and 46,XY 
DSD with suspected gonadal dysgenesis, AMH levels indi-
cate the existence of functional testicular tissue, (32, 33). 
Granulosa cells of primary and small antral ovarian fol-
licles produce only small amounts of AMH from late fetal 
life until menopause. In 46,XX DSD elevated AMH levels 
indicate ovotesticular DSD with usually functional ovarian 
First line investigations
• Serum testosterone (T), DHEA-S, 17OHP
• Imaging studies of pelvic organs (uterus, ovaries) and adrenal glands (ultrasound, CT, MRI)
Medical history; physical examination; bone age
Genetic analysis guided by a tentative diagnosis: Karyotype, aCGH/MLPA, NGS (panel, WES, WGS)
• DSD gene candidate analysis (e.g. for CYP21A2 or other genes (see Table 2)) or unbiased NGS, aCGH 
analysis from blood
• Tumor tissue characterization (e.g. for DICER1, p53)
Slow onset, progessive                                    Rapid onset
Work-up of the virilized girl at puberty
CAH/DSD*                                                  Adrenocortical (ACT) or gonadal tumor (GT)           
Second line investigations 
(chosen informed by results of first line investigations)
• Cortisol, ACTH, ACTH simulation test – For DD of different forms of CAH?
• Comprehensive serum steroid profiling LC-MSMS (alternatively from urine 
by GC-MS) – Specific pattern for CAH - Unspecific in tumors. 
• Dexamethasone test – DD: ACT, Cushing syndrome
• E2, LH, FSH, AMH, Inhibin B – HPG axis functionality? Sertoli cell 
function/testicular tissue?
• Repetitive and/or advanced imaging studies
• Diagnostic laparoscopy
• Catheter based sampling procedures
17OHP↗                                                                      DHEA-S↗                                                 T↗                                       
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tissue but dysgenetic testicular tissue (32). Tumor markers 
such as α-fetoprotein, β-human chorionic gonadotrophin, 
lactate dehydrogenase, inhibin, and cancer antigen 125 
are positive in 50% to 80% of malignant ovarian lesions, 
but may also be positive in 20% of benign ovarian germ 
cell tumors (4). Repetitive imaging studies may be neces-
sary, in case of unsolved tumor suspicion and/or localiza-
tion. If still unsuccessful, catheter procedures for adrenal 
vein sampling may be considered for diagnosing and lo-
calizing suspected adrenal tumors, whereas diagnostic 
laparoscopy and biopsy may be performed for suspected 
gonadal tumors.
Genetic tests are now standard for diagnostic workup 
of many disorders to confirm a diagnosis at the molecular 
level and allow for genetic counseling and prognostic 
evaluation. This may include a simple karyotype, an array 
comparative genomic hybridization, a candidate gene or an 
unbiased next-generation sequencing (eg, whole exome or 
genome sequencing) approach. The appropriate method for 
genetic testing depends on the suspected diagnosis and is 
best advised by a geneticist.
Returning to the Patient
First-line investigations showed a very high serum tes-
tosterone and normal values for DHEA-S and 17OHP, 
orientating the diagnosis toward a gonadal rather than 
an adrenal origin of androgen excess (Table 2). Gonadal 
dysgenesis was suspected because of elevated LH and FSH 
(FSH > LH), and undetectable estradiol (E2). AMH was 
low (0.53 ng/mL; normal value <9.00 ng/mL). Ultrasound 
revealed a prepubertally sized uterus, normal adrenals, and 
gonads that were first described as normal, but on later re-
view of images not clearly detectable; no tumor was found. 
Bone age was concordant with chronological age according 
the Greulich-Pyle method. The 24-hour urine steroid pro-
file excluded any form of nonclassic CAH and Cushing 
syndrome, but confirmed very high excretion of androgen 
metabolites (>3-fold of normal). The ACTH stimulation 
test showed normal reactivity of adrenal steroids, and the 
dexamethasone suppression test revealed normal inhibition 
of adrenal steroidogenesis. Overall, all these investigations 
pointed toward a gonadal origin of testosterone produc-
tion, whereas elevated LH and FSH paradoxically sug-
gested hypergonadotropic hypogonadism. Thus, gonadal 
dysgenesis owing to a DSD was suspected and genetic 
workup initiated.
Initially, conventional chromosomal analysis of 30 
lymphocytes (180 mitosis) revealed a 45,X karyotype 
compatible with TS (Fig.  2A). Further genetic examin-
ations in search of “hidden” Y-chromosome material in-
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comparative genomic hybridization (180  K) analyses 
(Fig. 2B–D). They uncovered a terminal heterozygous de-
letion of 9p24.3p23 and the presence of Yp11.32p11.31, 
with the karyotype described according to the International 
System for Human Cytogenomic Nomenclature (2016) 
as follows: 45,X.ish der (9)t(Y;9)(305J7-T7,SRY+).
arr[GRCh37]9p24.3p23(209020_12669909)x1,(X)
x1,Yp11.32p11.31(249520_2905060)x1. Ectopic presence 
of Sex Determining Region on Y (SRY) has been shown 
sufficient to induce testis development (34). However, the 
terminal heterozygous deletion of 9p24.3p23 resulted in 
partial monosomy of 9p (~12.46 Mb) with absence of 49 
genes including the pro-testis gene Doublesex and Mab-3 
Related Transcription Factor 1 (DMRT1), and explaining 
the female phenotype in our patient (Fig. 2).
Given that these results were consistent with a com-
plex form of gonadal dysgenesis with functionally ac-
tive testicular tissue, the patient underwent laparoscopy. 
Macroscopically atypical gonads were found on both sides 
(Fig.  3). Gonadectomy was performed to avoid further 
virilization and malignant degeneration because there is 
a high risk for germ cell cancer (GCC), arising from sur-
viving pluripotent germ cells in dysgenetic gonads har-
boring Y chromosomal material (35). Morphological and 
immunohistochemical analysis (Fig. 4) revealed a left gonad 
mostly differentiated as testis and characterized by Sertoli 
cell only tubules, extensive Leydig cell hyperplasia, and dis-
crete signs of dysgenesis (intracapsular growth of tubules, 
ovarian-type stroma) at the gonadal periphery, as well as 
a small area of streak gonadal tissue. The right gonad was 
composed of streak tissue only with limited and scattered 
granulosa cells. Follicles or isolated germ cells were not de-
tected by specialized immunohistochemical staining. There 
were no signs of in situ or invasive GCC, as indicated by 
negative SALL4 and OCT3/4 staining (not shown).
On follow-up, after removal of the gonads, testosterone 
values normalized (Table  2) and clitoromegaly reduced. 
The patient received psychosexual care and identified her-
self clearly in the female gender. Given the high LH/FSH 
values suggesting pubertal activation of the hypothalamic-
pituitary-gonadal axis, E2 replacement therapy was started 
2  months after gonadectomy to enable the development 
of secondary female sexual characteristics and to promote 
normal bone mass acquisition. The patient’s compliance 
with transdermal E2 patch treatment was initially rather 
poor, but improved under psychological guidance, so that 
E2 and FSH levels normalized under stepwise dose adjust-
ment (Table 2).
Discussion
We describe a girl who presented with spontaneous viriliza-
tion at puberty. High serum testosterone, LH and FSH, and 
a complex chromosomal rearrangement, including presence 
of Y chromosomal material initially suggested a diagnosis 
of TS with mosaicism for a second cell line. A normal or 
partly deleted Y chromosome can be found in 6% to 11% 
of women with TS. However, the girl lacked clinical fea-
tures associated with classic TS, such as typical facial char-
acteristics, short stature, and cardiac or renal anomalies. 
Instead, the unique chromosomal rearrangement, resulting 
in the combined presence of the testis-inducing gene SRY 
with absence of the pro-testis gene DMRT1 on 9p had led 
to partial gonadal (testicular) dysgenesis, manifest as uni-
lateral testis development with extensive Leydig cell hyper-
plasia resulting in high androgen production at puberty. 
The molecular genetic diagnosis and pathological findings 
are in line with hormonal results (ie, hypergonadotropic 
hypogonadism and testosterone levels well above the fe-
male reference range), but cannot explain why virilization 
did not occur already prenatally.
Early diagnosis and appropriate management of par-
tial gonadal dysgenesis is crucial because of a strongly 
Monosomy X: 
(X)x1











Figure 2. Genetic analyses performed in the girl presented in the case 
vignette. (A) Karyotype 45,X. (B-C) FISH analysis confirmed the pres-
ence of SRY and showed a suspicious hybridization pattern. (B) FISH 
analysis with LSI SRY(red)/CEPX(green) probes showing an unusual 
hybridization pattern. LSI SRY-signal on chromosome 9pter. (C) FISH 
analysis with SubTel-9p/9q-probe (9pter(green)/9qter(red)). No SubTel 
9p signal present on the derivative chromosome 9, only a red signal, 
no green signal. (D) Array-CGH analysis. Full genome profile from 
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increased (up to 50%) risk of gonadoblastoma and invasive 
GCC development (36, 37) Therefore, a systematic search 
for hidden Y-chromosome material should be performed in 
all TS girls with signs of virilization or with an unidentifi-




Figure 3. Pictures of gonads of the described patient at timepoint of laparoscopic gonadectomy. (A) Laparoscopic view on the in situ dysgenetic 
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Figure 4. Histologic workup of the dysgenetic gonads. (A-E) Left gonad. (A-B) Left gonad predominantly developed as testis, with a smaller zone of 
streak tissue at the periphery. (C) Detailed analysis shows Sertoli cell-only tubules and diffuse intertubular Leydig cell hyperplasia. (D) The testicular 
periphery reveals rete testis and a more dysgenetic area with intracapsular growth of testis tubules in a background of ovarian-type stroma. (E) The 
latter finding is confirmed by the presence of scattered FOXL2 positive (brown) granulosa cells. (F-H) Right streak gonad. (F) Follicles or isolated germ 
cells are not detected. (G) The stromal background contains some dispersed FOXL2 positive (brown) granulosa cells confirming the overall female 
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Gonadal (testicular) dysgenesis with increased risk of 
gonadoblastoma can also be associated with partial or 
complete deletion of distal chromosome 9 (41). The re-
current distal 9p microdeletion syndrome has a prevalence 
of <1/1,000,000 and is characterized by dysmorphic fea-
tures such as trigonocephaly, long philtrum, psychomotor 
retardation, speech problems, and atypical genitalia (42). 
The phenotype shows variable expressivity and is related 
to the size of the deletion, with cases of isolated 46,XY sex 
reversal without other dysmorphic features (43). Within 
this region, the strongest candidate for disrupted gonadal 
development is the DMRT1 gene, mapping to 9p24.3 (44). 
DMRT1 is a transcription factor expressed by both Sertoli 
and germ cells. It is critical for testis determination, differ-
entiation, and maintenance. DMRT1 haploinsufficiency is 
associated with abnormal testicular development, leading 
to germ cell loss and reduced or absent virilization of ex-
ternal genitalia (45-47). The particular genotype of sex 
reversal resulting from loss of DMRT1 is extremely rare, 
with only a few cases reported. Marsudi et al (45) reported 
on a 12-year-old female with short stature and cognitive 
impairment, mimicking TS. Genetic analysis revealed loss 
of the DMRT1 gene in a mosaic 45,XY,-9[8]/46,XY,r (9)
[29]/47,XY,+idic r (9)×2[1]/46,XY,idic r (9)[1]/46,XY[1] 
karyotype. Further research is required to better under-
stand the exact mechanism that underlies sex reversal 
caused by DMRT1 haploinsufficiency (48), as well as the 
delayed onset of virilization in our case.
Conclusion
Virilization at puberty is more complex than routinely 
thought. All efforts should be taken to identify the 
underlying cause as a malignant tumor may be found and on-
going virilization may result in irreversible bodily changes. 
Underlying ovarian or adrenal tumors should be excluded 
by imaging studies. Karyotyping and a thorough search for 
Y chromosomal material by quantitative PCR or FISH are 
essential components of the genetic evaluation. If Y material 
is found, prophylactic gonadectomy of dysgenetic gonads 
may be advised to prevent gonadoblastoma and invasive 
tumor development. The described case report highlights 
the importance of repeated and expanded biochemical and 
genetic workup to solve unusual cases. Complex genetic 
rearrangements can cause unique, unexpected phenotypes.
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